November 2025's High Growth Companies With Insider Influence

As the U.S. market navigates the aftermath of a record government shutdown, with major indices like the Dow Jones and Nasdaq experiencing fluctuations, investors are paying close attention to sectors that can weather such uncertainties. In this context, growth companies with high insider ownership present an intriguing opportunity, as they often demonstrate strong alignment between management and shareholder interests—a critical factor in navigating volatile market conditions.

Top 10 Growth Companies With High Insider Ownership In The United States

Click here to see the full list of 190 stocks from our Fast Growing US Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Abeona Therapeutics (ABEO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases, with a market cap of $268.41 million.

Operations: Abeona Therapeutics Inc. currently does not report any revenue segments, as it is focused on the development of gene and cell therapies for critical health conditions.

Insider Ownership: 10.4%

Abeona Therapeutics, a gene therapy company, has recently shown significant financial improvement with a net income of US$91.64 million for the first nine months of 2025, contrasting with a loss the previous year. With high insider ownership and no substantial selling in recent months, the company is positioned for growth. Its revenue is projected to increase significantly above market rates. The recent FDA program inclusion and new product coding enhance its potential market reach and operational efficiency.

• Navigate through the intricacies of Abeona Therapeutics with our comprehensive analyst estimates report here.
• According our valuation report, there's an indication that Abeona Therapeutics' share price might be on the cheaper side.

CapsoVision (CV)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CapsoVision, Inc. is a medical technology company that manufactures and markets endoscopic video imaging devices for gastrointestinal system imaging, with a market cap of $254.68 million.

Operations: The company generates revenue primarily from its Capsule Endoscopy segment, totaling $12.52 million.

Insider Ownership: 24.6%

CapsoVision is poised for growth with high insider ownership and no recent insider trading activity. The company forecasts revenue growth of 44.2% annually, outpacing the US market's 10.5%. Recent strategic moves include submitting an FDA application for a breakthrough device designation, enhancing its diagnostic capabilities in pancreatic cancer detection. Financially, CapsoVision faces challenges with less than one year of cash runway and limited financial data but recently strengthened its leadership by appointing a seasoned finance executive.

• Delve into the full analysis future growth report here for a deeper understanding of CapsoVision.
• In light of our recent valuation report, it seems possible that CapsoVision is trading beyond its estimated value.

RingCentral (RNG)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: RingCentral, Inc. offers cloud-based business communications, contact center, video, and hybrid event solutions globally with a market cap of approximately $2.37 billion.

Operations: RingCentral generates revenue of $2.49 billion from its Internet Software & Services segment, providing cloud communication solutions worldwide.

Insider Ownership: 10.2%

RingCentral demonstrates growth potential with substantial insider ownership, despite slower revenue growth forecasts compared to the US market. Recent product announcements, including the Customer Engagement Bundle and RingWEM Suite, position it to enhance customer interaction and operational efficiency. Financially, RingCentral has turned profitable this year with a net income of US$17.56 million in Q3 2025. It completed significant share buybacks and expanded its credit facility to manage upcoming debt maturities effectively.

• Take a closer look at RingCentral's potential here in our earnings growth report.
• Our comprehensive valuation report raises the possibility that RingCentral is priced lower than what may be justified by its financials.

Taking Advantage

• Explore the 190 names from our Fast Growing US Companies With High Insider Ownership screener here.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com